Form 4: Arcutis Biotherapeutics Director Patrick Heron Reports Stock Purchase

Director Patrick J. Heron reports purchasing 2,520 shares of Arcutis Biotherapeutics at an average price of $13.6178.

Summary

• On May 15, 2025, Patrick J. Heron, a director of Arcutis Biotherapeutics, Inc., purchased 2,520 shares of common stock.
• The purchase was made at a weighted average price of $13.6178 per share, with individual transactions ranging from $13.49 to $13.69.
• Following the transaction, Heron directly owns 18,826 shares and indirectly owns 17,494 shares through Frazier Life Sciences X, L.P., 8,785,284 shares through Frazier Life Sciences VIII, L.P., 7 shares through FHM Life Sciences VIII, L.L.C., and 23,688 shares through The Heron Living Trust 11/30/2004.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares can be seen as a positive sign, but it's a relatively small transaction in the context of the overall shareholding.

Positives

• The director's purchase could be interpreted as a positive signal about their confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. Investors often monitor such filings for signals about management's sentiment regarding the company's stock.

Stakeholder Impact

• The stock purchase by a director could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Patrick Heron, Director, Stock Purchase, SEC Form 4, Beneficial Ownership, Frazier Life Sciences